Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study

NCT05977673 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT05977673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05977673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Recruiting
Start date
May 23, 2024
Completion date
November 30, 2030
Enrollment
28 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma